GGrantIndex
← Leaderboards

Romi Gupta

Yale University

$2,402,166
Attributed
$2,601,488
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $457.9K · FY201825
$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$2,601,488 · 6

By mechanism

R01$1,599,344 · 1
R03$603,500 · 4
R21$398,644 · 1

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “In Vivo

Research focus

In VivoGrowthEffective TherapyMouse ModelPublic HealthExperimental StudyTumor GrowthDiagnosisDrug TargetingMediatingGenesSmall Hairpin RnaSmall Molecule InhibitorPathway InteractionsGeneticKnock-DownTumor ProgressionWomanSamplingCancer CellInnovationCell Culture TechniquesBaseCancer Therapy

Grant awards (15)

PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$325,732
R01 · FY2025 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$309,446
R01 · FY2024 · CA · contact PI
A novel cellular identity regulatory pathway that drives anokis resistance-mediated TNBC growth and metastasis$148,500
R03 · FY2024 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$319,217
R01 · FY2023 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$319,217
R01 · FY2022 · CA · contact PI
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS$325,732
R01 · FY2021 · CA · contact PI
A Novel Anoikis Effector that Drives Ovarian Cancer Metastasis$74,250
R03 · FY2021 · CA · contact PI
A Novel Anoikis Effector that Drives Ovarian Cancer Metastasis$74,250
R03 · FY2020 · CA · contact PI
A NOVEL EPIGENETIC IMMUNOTHERAPY FOR OVARIAN CANCER TREATMENT$74,250
R03 · FY2020 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$180,056
R21 · FY2019 · CA
PERSONALIZED THERAPY FOR p16-DEFICIENT MELANOMA$74,250
R03 · FY2019 · CA · contact PI
A NOVEL EPIGENETIC IMMUNOTHERAPY FOR OVARIAN CANCER TREATMENT$74,250
R03 · FY2019 · CA · contact PI
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$115,103
R21 · FY2018 · CA
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC$103,485
R21 · FY2018 · CA
PERSONALIZED THERAPY FOR p16-DEFICIENT MELANOMA$83,750
R03 · FY2018 · CA · contact PI